Skip to main content

JDRF is undergoing a transformation.
We are becoming Breakthrough T1D in October.

breakthrought1d logo
Type 1 technology

FreeStyle Libre system now compatible with smart insulin pens

Abbott’s FreeStyle Libre systems and Novo Nordisk’s smart insulin pens can now link up virtually to help people with type 1 manage their diabetes more easily.
JDRF logo placeholder for author profile picture
Kate Lawton 10 November 2022

A woman using a Libre flash sensor and Novo Nordisk smart insulin pen

What are the changes?

People who use this flash glucose monitoring system along with multiple daily injections can now view their glucose and insulin data together in the FreeStyle LibreLink app. The smartphone app can now record people’s insulin dosage history and show the time and the amount of insulin taken alongside their glucose levels.

With around 65% of people with type 1 diabetes in the UK using Libre monitors, this could benefit a considerable number of the type 1 community.

What is this type 1 tech?

The FreeStyle Libre 2 Sensor is a monitor that measures your blood glucose levels continuously. Users can see their current and recent blood glucose levels by scanning their phone over the device. The data is visible on the Freestyle LibreLink app on their phone to show much glucose is in their blood and whether this level is rising, dropping, or stable.

Novo Nordisk's smart insulin pens

Novo Nordisk’s smart insulin pens are devices to inject insulin that record the dose and time of insulin injections. The Freestyle LibreLink smartphone app can now communicate with both the Libre 2 and these smart pens to store information from both devices. This will allow users to easily view their glucose levels and insulin dosing data together.

How will this benefit people with type 1?

This could help lift some of the mental burden that comes with managing type 1 diabetes. It will help people understand how factors like medication, food and physical activity are affecting their glucose levels. This functionality can help people with type 1 take the right amount of insulin to keep their blood glucose levels more stable.

Neil Harris, General Manager of Abbott’s diabetes care business in the UK and Ireland, said: “Access to diabetes data empowers people by removing some of the guess-work related to the relentless management of the condition.”

More personalised healthcare

Users of this integrated system also have the option to share this detailed data with their healthcare team through the cloud-based data system, LibreView. This would enable healthcare professionals to be more informed about an individual’s condition to help personalise their care.

Feedback from the NHS

Professor Partha S. Kar, OBE – who is national specialty advisor, diabetes at NHS England and consultant endocrinologist at Portsmouth Hospitals NHS Trust – was involved in the pilot of the partnership. He said: “It’s wonderful to see FreeStyle Libre integrating with key insulin delivery data from the NovoPen devices. This could be a really positive step in helping to make day-to-day management easier for people with diabetes and their healthcare teams. The evidence is undeniable of the benefits broader access to tech can bring for people with diabetes, so I am pleased to see this connectivity now available in the UK.”

Other insulin devices to follow

Neil Harris added: “Abbott is continuing to pave the way for the future of diabetes care, not only through continuous innovation of the FreeStyle Libre systems, but also by working with Novo Nordisk and other insulin device companies to help further remove some of the daily burden for people with diabetes.”

Related news

Read more
Hybrid closed loop technology
Type 1 technology
19 December 2023

NICE Approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales

In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
T cell immune system
6 November 2023

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.

Read more
Illustration of the hybrid closed loop technology system, funded as part of treatment research for type 1 diabetes by JDRF.
Type 1 technology
21 August 2023

NICE’s latest consultation on hybrid closed loop

As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.